anti-trop-2 antibody-drug conjugate pbi-410
Generic: Anti-TROP-2 Antibody-drug Conjugate PBI-410
anti-trop-2 antibody-drug conjugate pbi-410: 1 clinical trial tracked.
anti-trop-2 antibody-drug conjugate pbi-410 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-trop-2 antibody-drug conjugate pbi-410, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
Primary endpoint: Phase 1: Number of patients with adverse events (AEs)
Interventionalopen500 targetStarted 2024-04Completion 2028-0217 sites · United StatesBiohaven Therapeutics Ltd.